报价延迟最少15分钟:2025/09/16 23:15 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
77.64 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
2.16/2.87
|
|
企业价值
43.24B
|
| 资产负债 |
|
每股账面净值
44.73
|
| 现金流量 |
|
现金流量率
0.05
|
| 损益表 |
|
收益
9.91B
|
|
每股收益
18.38
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/16 23:15 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world. |
